Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PROK

DatePrice TargetRatingAnalyst
9/30/2024Neutral
JP Morgan
9/10/2024$6.00Buy
Guggenheim
3/7/2024$3.00Equal-Weight
Morgan Stanley
1/2/2024Buy → Neutral
BofA Securities
7/25/2023$16.00Buy
BTIG Research
12/21/2022$15.00Buy
Jefferies
11/10/2022$13.00Equal-Weight
Morgan Stanley
10/18/2022$18.00Buy
UBS
More analyst ratings

$PROK
Press Releases

Fastest customizable press release news feed in the world

See more
  • ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 43rd Annual J.P. Morgan Healthcare ConferenceDate:January 15, 2025Time:7:30am PSTFormat:PresentationWebcast:Link   The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

    WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December: Evercore HealthCONx ConferenceDate:December 3, 2024Time:8:45am ETFormat:Fireside ChatWebcast:Link  Citi Global Healthcare ConferenceDate:December 4, 2024Format:One-on-one meetings   The live webcast for the Evercore fireside chat will be accessible through the "Events" section of the Investor Relations tab w

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

    FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed in that Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used Presented five posters at the ASN Kidney Week, including one late-breaking clinical trial and four posters on rilparencel's product characterization and MOAEnded the third quarter with $406.8 million in cash and cash equivalents and marketable securities, supporting operations into 2027 WINSTON-SALEM, N.C

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PROK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PROK
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PROK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PROK
SEC Filings

See more

$PROK
Leadership Updates

Live Leadership Updates

See more
  • ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

    Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentiall

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ProKidney Reports Business Updates and First Quarter 2024 Financial Results

    Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Strengthened leadership team with appointment of two key hires across Clinical and Technical OperationsEnded the first quarter with $329 million in cash and cash equivalents and marketable securities, su

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

    WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve kidney function in patients with type 2 diabetes mellitus and advanced kidney disease, we look forward to the REGEN-007 Phase 2 interim data readout mid-year," said Bruce Culleton, Ch

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PROK
Financials

Live finance-specific insights

See more
  • ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

    Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trialsManagement to host live webcast today at 8:00 a.m. ET WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ProKidney Reports Third Quarter Financial Results

    WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. "Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need," said James Coulston, Chief Financial Officer at ProKidney. "With cash expected to fund operations into the

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

    Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure and need for renal replacement therapy Dr. Bruce Culleton appointed ProKidney CEO following Dr. Tim Bertram's transition to advisory role Sufficient capital to fund operations into fourth quarter 2025 ProKidney to host conference call and webcast tomorrow at 8:00 a.m. ET WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellu

    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PROK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more